Welcome to our dedicated page for Exscientia Plc news (Ticker: EXAI), a resource for investors and traders seeking the latest updates and insights on Exscientia Plc stock.
Exscientia Plc (EXAI) is a pioneer in AI-driven drug discovery, transforming pharmaceutical research through automated small molecule design. This page serves as the definitive source for tracking the company's latest developments, offering investors and industry observers timely updates on its groundbreaking work.
Access comprehensive coverage of financial results, research milestones, and strategic partnerships that define Exscientia's progress. Our curated news collection includes press releases on clinical advancements, technology innovations, and regulatory developments essential for understanding the company's trajectory.
Key updates feature Exscientia's AI-optimized drug candidates, collaborations with leading pharmaceutical organizations, and insights into their automated discovery platform. The resource is particularly valuable for tracking how machine learning accelerates compound design while maintaining rigorous quality standards.
Bookmark this page for efficient monitoring of Exscientia's contributions to biopharmaceutical innovation. Return regularly to stay informed about how their AI-first approach continues to reshape drug development timelines and methodologies.
The Business Research Company's AI in Drug Discovery Global Market Report 2023 reveals a concentrated market with IBM holding 13.33% share. The market is projected to grow from $791.8 million in 2023 to $2.9 billion by 2027, at over 30% CAGR. Key players include Benevolent AI, Nvidia, and Exscientia. Opportunities mainly arise in small molecules, expected to reach $1.2 trillion in global sales by 2026. Companies are encouraged to invest in AI innovation labs and develop personalized treatments for rare diseases to leverage growth potential.
Exscientia (NASDAQ: EXAI) announced that its candidate EXS4318 has begun Phase 1 clinical trials in the U.S., marking its entry into the immunology & inflammation therapeutic area. This compound, developed with Bristol Myers Squibb, is a selective PKC theta inhibitor aimed at treating autoimmune diseases. Exscientia is eligible for milestone payments and tiered royalties on sales upon approval. This milestone highlights the efficacy of Exscientia's AI-driven drug design platform, which identified EXS4318 within 11 months, showcasing its commitment to rapid drug development.
Rallybio Corporation (NASDAQ: RLYB) has made significant strides in its mission to develop therapeutics for rare diseases, as indicated in its recent update. Key milestones include the upcoming Phase 1b proof-of-concept data for RLYB212 expected in Q1 2023 and initial data from a Phase 1 study of RLYB116 anticipated in H2 2023. The company's cash runway has been extended into Q1 2025 following a follow-on offering in November 2022, yielding $55 million in gross proceeds, bolstering its financial position for future developments.
Exscientia (NASDAQ: EXAI) has announced a breakthrough in identifying patient responders to its A2A receptor antagonist, EXS-21546. Highlighting new data, the company revealed the adenosine burden score (ABS) that predicts the effectiveness of the drug in combating tumor immunosuppression. Exscientia is set to confirm ABS's validity in its upcoming IGNITE-AI Phase 1/2 trial, which combines '546 with a checkpoint inhibitor for patients with relapsed renal cell carcinoma and non-small cell lung cancer. This research will be presented at the ESMO Immuno-Oncology Congress from December 7-9 in Geneva.
Exscientia announced the approval of the IGNITE-AI clinical trial for EXS-21546, an A2A receptor antagonist, targeting relapsed/refractory renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC). The trial aims to enroll up to 110 patients to assess safety, efficacy, and pharmacokinetics. Notably, a unique biomarker signature will guide patient selection. The trial's first phase will establish the maximum tolerated dose, followed by an expansion phase to confirm efficacy. This is a significant step for Exscientia, enhancing its precision medicine approach.
Exscientia plc (Nasdaq: EXAI) reported results for Q3 2022, revealing revenues of $7.0 million, a decline from $19.6 million in Q3 2021. R&D expenses surged to $40.9 million from $14.4 million year-over-year, reflecting growth in its portfolio. The firm posted a net loss of $39.5 million, worsening from $5.6 million in the previous year. Exscientia announced strategic collaboration with MD Anderson Cancer Center and expansion into biologics. Cash balance stood at $624.7 million.
Conference call scheduled for November 15 at 1:30 PM GMT.
Exscientia plc (EXAI) and MD Anderson Cancer Center announced a strategic collaboration to leverage AI in oncology drug discovery. This partnership aims to develop novel small-molecule therapies by utilizing Exscientia’s precision medicine platform alongside MD Anderson’s drug development expertise. The collaboration will focus on identifying new anti-cancer compounds for clinical trials, enhancing the efficiency of drug development and patient stratification. Both organizations will jointly contribute to advancing promising candidates from the discovery phase to proof-of-concept trials.
Exscientia plc (NASDAQ: EXAI) is set to release its third-quarter financial results for the period ending September 30, 2022, on November 15, 2022, before U.S. market openings. A conference call and webcast will follow at 1:30 p.m. GMT / 8:30 a.m. EST to discuss the results and provide a business update. Exscientia specializes in AI-driven drug discovery, focusing on precision oncology and other therapeutic areas, aiming to deliver innovative treatment solutions.
Rallybio Corporation (Nasdaq: RLYB) reported financial results for Q3 2022, showing a net loss of $18.4 million and R&D expenses of $12.1 million. The company presented promising preliminary results from the Phase 1b study of RLYB212, demonstrating rapid platelet elimination. Positive topline results from the Phase 1 study of RLYB116 indicated over a 99% reduction in free C5 levels, with potential for less frequent dosing. Rallybio's cash position as of September 30, 2022, was $132.4 million, sufficient to fund operations into Q1 2024.
Exscientia (NASDAQ: EXAI) has announced the launch of an automated biologics laboratory in Oxford, enhancing its platform to design human antibodies. This development follows AI advancements in virtual biologics design and aims to integrate AI with high-throughput profiling. The laboratory will allow Exscientia to create optimized antibodies rapidly, tapping into a database of paired human antibody sequences. The goal is to revolutionize biologic drug discovery, potentially doubling the target market as antibodies are prominent in top-selling drugs.
